



Clinical trial results:

A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together)

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2020-002979-35 |
| Trial protocol | GB PL IT |
| Global end of trial date | 17 February 2023 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v2 (current) |
| This version publication date | 26 April 2024 |
| First version publication date | 06 March 2024 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 209348 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04676724 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | IND: 122685 |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS |
| Public contact | GlaxoSmithKline, GSK Response Center, 1 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 06 April 2023 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 17 February 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Efficacy: To investigate the efficacy of two different durations of GSK3228836 followed by up to 24 weeks of PegIFN therapy in participants with CHB on stable NA therapy.

Protection of trial subjects:

None

Background therapy:

Participants were to continue their stable nucleos(t)ide analogue (NA) therapy for the duration of the study.

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 28 January 2021 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Canada: 2 |
| Country: Number of subjects enrolled | China: 15 |
| Country: Number of subjects enrolled | Italy: 5 |
| Country: Number of subjects enrolled | Japan: 13 |
| Country: Number of subjects enrolled | Korea, Republic of: 18 |
| Country: Number of subjects enrolled | Poland: 5 |
| Country: Number of subjects enrolled | Russian Federation: 27 |
| Country: Number of subjects enrolled | South Africa: 1 |
| Country: Number of subjects enrolled | Spain: 11 |
| Country: Number of subjects enrolled | United Kingdom: 2 |
| Country: Number of subjects enrolled | United States: 9 |
| Worldwide total number of subjects | 108 |
| EEA total number of subjects | 21 |

Notes:

Subjects enrolled per age group

| | |
|--|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 | 0 |

| | |
|--|-----|
| wk | |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 103 |
| From 65 to 84 years | 5 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants who were on stable NA therapy randomized 1:1 to receive 300 mg/wk GSK3228836 for 24 wks+ PegIFN 180 mcg/wk 24 weeks, on-treatment until wk 48 and off-treatment from Week 48-72 in Arm1 & 300 mg/wk GSK3228836 for 12wks + PegIFN 180 mcg/wk for 24wks, on-treatment until wk 36 and off-treatment follow-up from Weeks 36 to 60 and 72 in arm2.

Pre-assignment

Screening details:

There were 108 participants enrolled in this study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--|
| Are arms mutually exclusive? | Yes |
| Arm title | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) |

Arm description:

Participants on stable NA therapy received 300mg/week GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 microgram per week (mcg/week) up to 24 weeks.

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | PegIFN |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

PegIFN180 180 mcg once a week up to 24 weeks.

| | |
|--|---------------------------------|
| Investigational medicinal product name | GSK3228836 and PegINF |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GSK3228836 300mg once a week for 24 weeks, plus a loading dose of GSK3228836 300mg on Day 4 and 11.

| | |
|------------------|--|
| Arm title | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) |
|------------------|--|

Arm description:

Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks.

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | GSK3228836 and PegINF |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

GSK3228836 300mg once a week for 12 weeks, plus a loading dose of GSK3228836 300mg on Day 4

and 11.

| | |
|--|---------------------------------|
| Investigational medicinal product name | PegIFN |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

PegIFN180 180 mcg once a week up to 24 weeks.

| Number of subjects in period 1 | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) |
|---------------------------------------|--|--|
| Started | 55 | 53 |
| Completed | 49 | 50 |
| Not completed | 6 | 3 |
| Consent withdrawn by subject | 3 | 2 |
| Physician decision | - | 1 |
| Adverse event, non-fatal | 2 | - |
| Lost to follow-up | 1 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) |
|-----------------------|--|

Reporting group description:

Participants on stable NA therapy received 300mg/week GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 microgram per week (mcg/week) up to 24 weeks.

| | |
|-----------------------|--|
| Reporting group title | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) |
|-----------------------|--|

Reporting group description:

Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks.

| Reporting group values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | Total |
|---|--|--|-------|
| Number of subjects | 55 | 53 | 108 |
| Age categorical Units: Subjects | | | |
| Adults (18-64 years) | 50 | 53 | 103 |
| From 65-84 years | 5 | 0 | 5 |
| Age continuous Units: years | | | |
| arithmetic mean | 45.5 | 45.5 | |
| standard deviation | ± 10.73 | ± 9.35 | - |
| Sex: Female, Male Units: Participants | | | |
| Female | 11 | 20 | 31 |
| Male | 44 | 33 | 77 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| ASIAN | 30 | 26 | 56 |
| BLACK OR AFRICAN AMERICAN | 3 | 3 | 6 |
| WHITE | 22 | 24 | 46 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Mixed Race | 0 | 0 | 0 |

End points

End points reporting groups

| | |
|---|--|
| Reporting group title | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) |
| Reporting group description: Participants on stable NA therapy received 300mg/week GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 microgram per week (mcg/week) up to 24 weeks. | |
| Reporting group title | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) |
| Reporting group description: Participants on stable NA therapy received 300mg/week GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 mcg/week up to 24 weeks. | |

Primary: Treatment Arm 1 - Percentage of participants achieving sustained virologic response (SVR) for 24 weeks after end of treatment

| | |
|---|---|
| End point title | Treatment Arm 1 - Percentage of participants achieving sustained virologic response (SVR) for 24 weeks after end of treatment ^{[1][2]} |
| End point description: Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Intent to Treat (ITT) Set that included all randomized participants. Percentage values are rounded-off. | |
| End point type | Primary |
| End point timeframe: Up to 24 weeks off treatment (Study Weeks 48 to 72) | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|-----------------------------------|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 55 ^[3] | | | |
| Units: Percentage of Participants | 9 | | | |

Notes:

[3] - Intent to Treat (ITT) Set

Statistical analyses

No statistical analyses for this end point

Primary: Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment

| | |
|-----------------|---|
| End point title | Treatment Arm 2 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment ^{[4][5]} |
|-----------------|---|

End point description:

Sustained virologic response is defined as undetectable levels of Hepatitis B surface antigen (HBsAg) and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as HBsAg and HBV DNA levels were less than (<) Lower limit of quantitation (LLOQ) at the planned end of sequential treatment of GSK3228836 and PegIFN treatment which is sustained for 24 weeks post-GSK3228836 and PegIFN treatment in the absence of any rescue medication. Intent to Treat (ITT) Set that included all randomized participants. Percentage values are rounded-off.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 24 weeks off treatment (Study Weeks 36 to 60)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|-----------------------------------|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[6] | | | |
| Units: Percentage of Participants | 15 | | | |

Notes:

[6] - Intent to Treat (ITT) Set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Percentage of participants achieving HBsAg and HBV DNA < lower limit of quantitation (LLOQ)

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Percentage of participants achieving HBsAg and HBV DNA < lower limit of quantitation (LLOQ) ^[7] |
|-----------------|---|

End point description:

Percentage of participants achieving HBsAg and HBV DNA <LLOQ were reported. Intent to Treat (ITT) Set that included all randomized participants. Percentage values are rounded-off.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

End of treatment (up to 48 weeks) and up to 24 weeks off treatment (OTT) follow-up (FUP) (Study Weeks 48 to 72)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[8] | | | |
| Units: Percentage of Participants | | | | |
| End of treatment (up to 48 weeks) n=38 | 15 | | | |
| Up to 24 weeks OTT FUP (Study Weeks 48 to 72) n=49 | 13 | | | |

Notes:

[8] - Intent to Treat (ITT) Set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ)

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Percentage of Participants Achieving HBsAg and HBV DNA < Lower Limit of Quantitation (LLOQ) ^[9] |
|-----------------|---|

End point description:

Percentage of participants achieving HBsAg and HBV DNA <LLOQ were reported. Intent to Treat (ITT) Set that included all randomized participants. Percentage values are rounded-off.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 50 ^[10] | | | |
| Units: Percentage of Participants | | | | |
| End of treatment (up to 48 weeks) n=36 | 15 | | | |
| Up to 24 weeks OTT FUP (Study Weeks 36 to 60) n=50 | 17 | | | |
| Up to 36 weeks OTT FUP (Study Weeks 36 to 72) n=50 | 15 | | | |

Notes:

[10] - Intent to Treat (ITT) Set

Statistical analyses

Secondary: Treatment Arm 1: Percentage of Participants with Categorical Changes from Baseline in HBsAg Values

| | |
|-----------------|--|
| End point title | Treatment Arm 1: Percentage of Participants with Categorical Changes from Baseline in HBsAg Values ^[11] |
|-----------------|--|

End point description:

Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of <0.5, greater than or equal to (\geq) 0.5, ≥ 1 , ≥ 1.5 , and ≥ 3 log₁₀ international units per milliliter (IU/mL). The 'HBsAg < LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. Percentage values are rounded-off.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, End of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[12] | | | |
| Units: Percentage of Participants | | | | |
| HBsAg <LLOQ- EOT up to 48 weeks, n=36 | 18 | | | |
| HBsAg<LLOQ- 24 Wk OTT (Wks 48 to 72) n=49 | 13 | | | |
| HBsAg decline <0.5- EOT up to 48 weeks, n=36 | 24 | | | |
| HBsAg decline <0.5- 24 Wk OTT (Wks 48 to 72) n=49 | 45 | | | |
| HBsAg decline ≥ 0.5 - EOT up to 48 weeks, n=36 | 42 | | | |
| HBsAg decline ≥ 0.5 -24 Wk OTT (Wks 48 to 72) n=49 | 44 | | | |
| HBsAg decline ≥ 1 - EOT up to 48 weeks, n=36 | 33 | | | |
| HBsAg decline ≥ 1 - 24 Wk OTT (Wks 48 to 72) n=49 | 36 | | | |
| HBsAg decline ≥ 1.5 - EOT up to 48 weeks, n=36 | 27 | | | |
| HBsAg decline ≥ 1.5 - 24 Wk OTT (Wks 48 to 72) n=49 | 36 | | | |
| HBsAg decline ≥ 3 , EOT up to 48 weeks, n=36 | 20 | | | |
| HBsAg decline ≥ 3 - 24 Wk OTT (Wks 48 to 72) n=49 | 27 | | | |

Notes:

[12] - Intent to Treat (ITT) Set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Percentage of Participants with Categorical Changes from Baseline in HBsAg Values

| | |
|-----------------|--|
| End point title | Treatment Arm 2: Percentage of Participants with Categorical Changes from Baseline in HBsAg Values ^[13] |
|-----------------|--|

End point description:

Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of <0.5, greater than or equal to (\geq) 0.5, ≥ 1 , ≥ 1.5 , and ≥ 3 log₁₀ international units per milliliter (IU/mL). The 'HBsAg < LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from baseline values. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60) and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 50 ^[14] | | | |
| Units: Percentage of Participants | | | | |
| HBsAg <LLOQ- EOT up to 36 weeks, n=36 | 15 | | | |
| HBsAg<LLOQ-24 Wk OTT (Wks 36 to 60) n=50 | 17 | | | |
| HBsAg<LLOQ-36 Wk OTT (Wks 36 to 72) n=50 | 15 | | | |
| HBsAg decline <0.5-EOT up to 36 weeks, n=36 | 26 | | | |
| HBsAg decline <0.5- 24 Wk OTT (Wks 36 to 60) n=50 | 42 | | | |
| HBsAg decline <0.5- 36 Wk OTT (Wks 36 to 72) n=50 | 43 | | | |
| HBsAg decline ≥ 0.5 -EOT up to 36 weeks, n=36 | 42 | | | |
| HBsAg decline ≥ 0.5 - 24 Wk OTT (Wks 36 to 60) n=50 | 51 | | | |
| HBsAg decline ≥ 0.5 - 36 Wk OTT (Wks 36 to 72) n=50 | 47 | | | |

| | | | | |
|---|----|--|--|--|
| HBsAg decline ≥ 1 - EOT up to 36 weeks, n=36 | 34 | | | |
| HBsAg decline ≥ 1 -24 Wk OTT (Wks 36 to 60) n=50 | 34 | | | |
| HBsAg decline ≥ 1 - 36 Wk OTT (Wks 36 to 72) n=50 | 32 | | | |
| HBsAg decline ≥ 1.5 - EOT up to 36 weeks, n=36 | 28 | | | |
| HBsAg decline ≥ 1.5 - 24 Wk OTT (Wks 36 to 60) n=50 | 23 | | | |
| HBsAg decline ≥ 1.5 - 36 Wk OTT (Wks 36 to 72) n=50 | 19 | | | |
| HBsAg decline ≥ 3 -EOT up to 36 weeks, n=36 | 15 | | | |
| HBsAg decline ≥ 3 - 24 Wk OTT (Wks 36 to 60) n=50 | 17 | | | |
| HBsAg decline ≥ 3 - 36 Wk OTT (Wks 36 to 72) n=50 | 17 | | | |

Notes:

[14] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Number of Participants with Alanine Aminotransferase (ALT) Normalization

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Number of Participants with Alanine Aminotransferase (ALT) Normalization ^[15] |
|-----------------|---|

End point description:

The ALT normalization (ALT \leq upper limit of normal [ULN]) over time in absence of rescue medication in participants with baseline ALT > ULN over time. Participants who achieved ALT normalization were reported. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (study week 48 to week 72)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---------------------------------------|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 55 ^[16] | | | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| ALT > ULN, at Baseline n=55 | 4 | | | |
| End of Treatment (up to 48 weeks) n=4 | 0 | | | |

| | | | | |
|---|---|--|--|--|
| Up to 24 weeks OTT FUP (Study Weeks 48 to 72) n=4 | 2 | | | |
|---|---|--|--|--|

Notes:

[16] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Number of Participants with Alanine Aminotransferase (ALT) Normalization

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Number of Participants with Alanine Aminotransferase (ALT) Normalization ^[17] |
|-----------------|---|

End point description:

The ALT normalization (ALT ≤ upper limit of normal [ULN]) over time in absence of rescue medication in participants with baseline ALT > ULN and ALT data at that visit. Participants who achieved ALT normalization were reported. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[18] | | | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| ALT > ULN, at Baseline n=53 | 10 | | | |
| End of Treatment (up to 36 weeks) n=7 | 1 | | | |
| Up to 24 weeks OTT FUP (Study Weeks 36 to 60) n=9 | 5 | | | |
| Up to 36 weeks OTT FUP (Study Weeks 36 to 72) n=9 | 6 | | | |

Notes:

[18] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Number of Participants with HBe Antibody (Anti-HBeAg) Levels

| | |
|---|---|
| End point title | Treatment Arm 1: Number of Participants with HBe Antibody (Anti-HBeAg) Levels ^[19] |
| End point description: Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. | |
| End point type | Secondary |
| End point timeframe: At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72) | |
| Notes: [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was descriptive, hence no statistical analysis to report. | |

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 13 ^[20] | | | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| At Baseline n=13 | 2 | | | |
| End of Treatment (up to 48 weeks) n=9 | 5 | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=13 | 4 | | | |

Notes:

[20] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Number of Participants with HBe Antibody (Anti-HBeAg) Levels

| | |
|---|---|
| End point title | Treatment Arm 2: Number of Participants with HBe Antibody (Anti-HBeAg) Levels ^[21] |
| End point description: Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. | |
| End point type | Secondary |
| End point timeframe: At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72) | |
| Notes: [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was descriptive, hence no statistical analysis to report. | |

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 14 ^[22] | | | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| At Baseline n=14 | 1 | | | |
| End of Treatment (up to 36 weeks) n=9 | 1 | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=14 | 1 | | | |
| 36 weeks OTT FUP (Study Weeks 36 to week 72) n=14 | 0 | | | |

Notes:

[22] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Mean Change from Baseline in HBe antibody levels

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Mean Change from Baseline in HBe antibody levels ^[23] |
|-----------------|---|

End point description:

Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 13 ^[24] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 48 weeks) n=9 | -1.04 (± 1.133) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72)- n=13 | -0.81 (± 1.044) | | | |

Notes:

[24] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Mean Change from Baseline in HBe antibody levels

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Mean Change from Baseline in HBe antibody levels ^[25] |
|-----------------|---|

End point description:

Blood samples were collected to assess HBe antibody levels and results reported are for baseline HBeAg positive participants. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, End of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 13 ^[26] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 36 weeks) n=9 | -0.52 (± 0.598) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=12 | -0.58 (± 0.766) | | | |
| Up to 36 weeks OTT FUP (study week 36 to 72) n=13 | -0.65 (± 0.787) | | | |

Notes:

[26] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Actual values of HBsAg levels

| | |
|-----------------|--|
| End point title | Treatment Arm 1: Actual values of HBsAg levels ^[27] |
|-----------------|--|

End point description:

Blood samples were collected from participants to assess HBsAg over time at indicated time points. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. The unit of measure is log10 International Units Per Milliliter (IU/mL).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 54 ^[28] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline n=55 | 3.34 (± 0.555) | | | |
| End of Treatment (up to 48 weeks) n=36 | 1.52 (± 2.071) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=49 | 1.72 (± 2.043) | | | |

Notes:

[28] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Actual values of HBsAg levels

| | |
|-----------------|--|
| End point title | Treatment Arm 2: Actual values of HBsAg levels ^[29] |
|-----------------|--|

End point description:

Blood samples were collected from participants to assess HBsAg over time at indicated time points. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. The unit of measure is log10 International Units Per Milliliter (IU/mL).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[30] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline n=53 | 3.32 (± 0.622) | | | |
| End of Treatment (up to 36 weeks) n=36 | 1.70 (± 0.491) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=49 | 2.12 (± 1.897) | | | |
| Up to 36 weeks OTT FUP (study week 36 to 72) n=48 | 2.12 (± 1.830) | | | |

Notes:

[30] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Mean Change from Baseline in HBsAg levels

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Mean Change from Baseline in HBsAg |
|-----------------|---|

End point description:

Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[32] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 48 weeks) n=36 | -1.76 (± 1.726) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=49 | -1.58 (± 1.722) | | | |

Notes:

[32] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Mean Change from Baseline in HBsAg levels

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Mean Change from Baseline in HBsAg |
|-----------------|---|

End point description:

Blood samples were collected to assess HBsAg change from baselines levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|---|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[34] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 36 weeks) n=36 | -1.54 (± 1.567) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=49 | -1.20 (± 1.458) | | | |
| Up to 36 weeks OTT FUP (study week 36 to 72) n=48 | -1.20 (± 1.460) | | | |

Notes:

[34] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Actual values of HBV DNA levels

| | |
|-----------------|--|
| End point title | Treatment Arm 1: Actual values of HBV DNA levels ^[35] |
|-----------------|--|

End point description:

Blood samples were collected to assess HBV DNA levels. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 55 ^[36] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline n=55 | 0.64 (± 0.796) | | | |
| End of Treatment (up to 48 weeks) n=35 | 0.97 (± 0.629) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=47 | 0.17 (± 0.438) | | | |

Notes:

[36] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Actual values of HBV DNA levels

| | |
|-----------------|--|
| End point title | Treatment Arm 2: Actual values of HBV DNA levels ^[37] |
|-----------------|--|

End point description:

Blood samples were collected to assess HBV DNA levels. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[38] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline n=53 | 0.57 (± 0.687) | | | |
| End of treatment (up to 36 weeks) n=35 | 0.70 (± 0.700) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=49 | 0.34 (± 0.579) | | | |
| Up to 36 weeks OTT FUP (study week 36 to 72) n=48 | 0.35 (± 0.587) | | | |

Notes:

[38] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Mean Change from Baseline in HBV DNA Levels

| | |
|-----------------|--|
| End point title | Treatment Arm 1: Mean Change from Baseline in HBV DNA Levels ^[39] |
|-----------------|--|

End point description:

Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 47 ^[40] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of treatment (up to 48 weeks) n=35 | 0.40 (± 0.945) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=47 | -0.39 (± 0.727) | | | |

Notes:

[40] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Mean Change from Baseline in HBV DNA Levels

| | |
|-----------------|--|
| End point title | Treatment Arm 2: Mean Change from Baseline in HBV DNA Levels ^[41] |
|-----------------|--|

End point description:

Blood samples were collected to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[42] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 36 weeks) n=35 | 0.21 (± 0.925) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=49 | -0.21 (± 0.876) | | | |
| up to 36 weeks OTT FUP (study week 36 to 72) n=48 | -0.22 (± 0.754) | | | |

Notes:

[42] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Actual values of Hepatitis B virus e-antigen (HBeAg) levels

| | |
|-----------------|--|
| End point title | Treatment Arm 1: Actual values of Hepatitis B virus e-antigen (HBeAg) levels ^[43] |
|-----------------|--|

End point description:

Blood samples were collected to assess HBeAg levels. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 55 ^[44] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline, n=55 | 14.221 (± 69.3438) | | | |
| End of Treatment (up to 48 weeks) n=10 | 0.250 (± 0.4193) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=15 | 1.197 (± 2.4945) | | | |

Notes:

[44] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Actual values of Hepatitis B virus e-antigen (HBeAg) levels

| | |
|-----------------|--|
| End point title | Treatment Arm 2: Actual values of Hepatitis B virus e-antigen (HBeAg) levels ^[45] |
|-----------------|--|

End point description:

Blood samples were collected to assess HBeAg levels. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|---|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[46] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline, n=53 | 8.510 (± 42.1588) | | | |
| End of Treatment (up to 36 weeks) n=12 | 3.008 (± 6.2682) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=14 | 3.410 (± 6.0421) | | | |
| Up to 36 weeks OTT FUP (study week 36 to 72) n=15 | 2.797 (± 4.8973) | | | |

Notes:

[46] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Mean Change from Baseline in HBeAg Levels

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Mean Change from Baseline in HBeAg |
|-----------------|---|

End point description:

Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|---|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 ^[48] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 48 weeks) n=10 | -21.774 (± 65.4276) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=15 | -19.482 (± 55.1948) | | | |

Notes:

[48] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Mean Change from Baseline in HBeAg Levels

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Mean Change from Baseline in HBeAg |
|-----------------|---|

End point description:

Blood samples were collected to assess HBeAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|---|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 15 ^[50] | | | |
| Units: Log10 IU/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 36 weeks) n=12 | -5.270 (± 8.8942) | | | |
| Up to 24 weeks OTT FUP (study week 36 to 60) n=14 | -26.384 (± 80.2108) | | | |
| Up to 36 weeks OTT FUP (study week 36 to 72) n=15 | -26.345 (± 77.2836) | | | |

Notes:

[50] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Actual values of HBs antibody levels

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Actual values of HBs antibody levels ^[51] |
|-----------------|---|

End point description:

Blood samples were collected to assess HBs antibody levels. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks) and up to 24 weeks off treatment follow-up (study week 48 to week 72)

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 54 ^[52] | | | |
| Units: Log10 IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline, n=54 | 0.62 (± 0.271) | | | |
| End of Treatment (up to 48 weeks), n=36 | 1.06 (± 0.903) | | | |
| Up to 24 weeks OTT FUP (Study Weeks 48 to 72) n=49 | 0.82 (± 0.718) | | | |

Notes:

[52] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Actual values of HBs Antibody Levels

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Actual values of HBs Antibody Levels ^[53] |
|-----------------|---|

End point description:

Blood samples were collected to assess HBs antibody levels. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[54] | | | |
| Units: Log10 IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline, n=53 | 0.69 (± 0.204) | | | |
| End of Treatment (up to 36 weeks) n=35 | 0.87 (± 0.491) | | | |
| Up to 24 weeks OTT FUP (Study Weeks 36 to 60) n=49 | 0.80 (± 0.521) | | | |
| Up to 36 weeks OTT FUP (Study Weeks 36 to 72) n=49 | 0.76 (± 0.481) | | | |

Notes:

[54] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Mean Change from Baseline in HBs antibody levels

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Mean Change from Baseline in HBs antibody levels ^[55] |
|-----------------|---|

End point description:

Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 48 ^[56] | | | |
| Units: Log10 IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of treatment (up to 48 weeks) n=35 | 0.42 (± 0.934) | | | |
| Up to 24 weeks OTT FUP (Study Weeks 48 to 72) n=48 | 0.18 (± 0.757) | | | |

Notes:

[56] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Mean Change from Baseline in HBs antibody levels

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Mean Change from Baseline in HBs antibody levels ^[57] |
|-----------------|---|

End point description:

Blood samples were collected to assess HBs antibody levels over time. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[58] | | | |
| Units: Log10 IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 36 weeks) n=35 | 0.18 (± 0.450) | | | |
| Up to 24 weeks OTT FUP (Study Weeks 36 to 60) n=49 | 0.09 (± 0.487) | | | |
| Up to 36 weeks OTT FUP (Study Weeks 36 to 72) n=49 | 0.05 (± 0.453) | | | |

Notes:

[58] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Actual values of ALT

| | |
|-----------------|---|
| End point title | Treatment Arm 1: Actual values of ALT ^[59] |
|-----------------|---|

End point description:

Mean values over time for ALT are reported here. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|---|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 55 ^[60] | | | |
| Units: International units per Liter (IU/L) | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline, n=55 | 22.7 (± 13.97) | | | |
| End of Treatment (up to 48 weeks) n=36 | 53.1 (± 60.61) | | | |
| Up to 24 weeks OTT FUP (Study Weeks 48 to 72) n=49 | 19.2 (± 9.77) | | | |

Notes:

[60] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Actual values of ALT

| | |
|-----------------|---|
| End point title | Treatment Arm 2: Actual values of ALT ^[61] |
|-----------------|---|

End point description:

Mean values over time for ALT are reported here. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|---|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 53 ^[62] | | | |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| At Baseline, n=53 | 26.9 (± 19.16) | | | |
| End of treatment (up to 36 weeks), n=35 | 55.3 (± 46.60) | | | |
| Up to 24 weeks OTT FUP (Study Weeks 36 to 60) n=49 | 22.1 (± 13.30) | | | |
| Up to 36 weeks OTT FUP (Study Weeks 36 to 72) n=48 | 23.5 (± 15.61) | | | |

Notes:

[62] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1: Change from Baseline in ALT

| | |
|-----------------|--|
| End point title | Treatment Arm 1: Change from Baseline in ALT ^[63] |
|-----------------|--|

End point description:

Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 48 weeks), and up to 24 weeks off treatment follow-up (Study Weeks 48 to 72)

Notes:

[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[64] | | | |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of Treatment (up to 48 weeks) n=36 | 27.6 (± 56.05) | | | |
| Up to 24 weeks OTT FUP (study week 48 to 72) n=49 | -3.8 (± 9.86) | | | |

Notes:

[64] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2: Change from Baseline in ALT

| | |
|-----------------|--|
| End point title | Treatment Arm 2: Change from Baseline in ALT ^[65] |
|-----------------|--|

End point description:

Blood samples were collected to assess ALT values. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At baseline, end of treatment (up to 36 weeks), up to 24 weeks off treatment follow-up (Study Weeks 36 to 60), and up to 36 weeks off treatment follow-up (Study Weeks 36 to 72)

Notes:

[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|--|--|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 49 ^[66] | | | |
| Units: IU/L | | | | |
| arithmetic mean (standard deviation) | | | | |
| End of treatment (up to 36 weeks), n=35 | 27.8 (± 40.55) | | | |
| Up to 24 weeks OTT FUP (Study Weeks36 to 60) n=49 | -4.3 (± 17.50) | | | |
| Up to 36 weeks OTT FUP (Study Weeks36 to 72) n=48 | -3.1 (± 18.65) | | | |

Notes:

[66] - ITT set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 1 - Median Time to ALT normalization in absence of rescue medication for 24 Weeks Off Treatment

| | |
|-----------------|---|
| End point title | Treatment Arm 1 - Median Time to ALT normalization in absence of rescue medication for 24 Weeks Off Treatment ^[67] |
|-----------------|---|

End point description:

Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT>ULN. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. The estimate for Median Time to Event (Weeks) is 99999 (non-estimable-NE) for Arm 1 because the survival curve did not reach below 0.5 at the last timepoint. The corresponding 95% CI's upper limit is 99999 (non-estimable-NE) because the number of events in Arm 1 was too small to provide an estimate.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 24 weeks off treatment (Study Week 48 to 72)

Notes:

[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|----------------------------------|--|--|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 4 ^[68] | | | |
| Units: Weeks | | | | |
| median (confidence interval 95%) | 99999 (6.3 to 99999) | | | |

Notes:

[68] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment Arm 2 - Median Time to ALT normalization in absence of rescue medication for 24 Weeks Off Treatment

| | |
|-----------------|---|
| End point title | Treatment Arm 2 - Median Time to ALT normalization in absence of rescue medication for 24 Weeks Off Treatment ^[69] |
|-----------------|---|

End point description:

Time to ALT normalization in absence of rescue medication were measured in participants having Baseline ALT>ULN. Intent-to-Treat Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 24 weeks off treatment (Study Weeks 36 to 60)

Notes:

[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was descriptive, hence no statistical analysis to report.

| | | | | |
|----------------------------------|---|--|--|--|
| End point values | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 10 ^[70] | | | |
| Units: Weeks | | | | |
| median (confidence interval 95%) | 4.1 (1.1 to 47.1) | | | |

Notes:

[70] - Intent to Treat (ITT) Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving Sustained Virologic Response (SVR) up to 24 weeks off-treatment for Comparison of Efficacy Between Different Treatment Durations

| | |
|-----------------|---|
| End point title | Percentage of Participants Achieving Sustained Virologic Response (SVR) up to 24 weeks off-treatment for Comparison of Efficacy Between Different Treatment Durations |
|-----------------|---|

End point description:

Sustained virologic response is defined as undetectable levels of HBsAg and Hepatitis-B virus deoxy-ribonucleic acid (HBV DNA) on treatment. The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication. The point estimate for the difference in SVR and its respective credible interval (CI) were evaluated at 24 weeks off of planned treatment for both arms. The comparison of efficacy is between treatment durations and timepoint corresponds to Week 72 in Arm 1 and Week 60 in Arm 2. 95% CI refers here as credible interval. Intent to Treat (ITT) Set that included all randomized participants.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 24 weeks off treatment (Treatment Arm 1: Study Weeks 48 to 72 and Treatment Arm 2: Study Weeks 36 to 60)

| | | | | |
|-----------------------------------|---|---|--|--|
| End point values | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) | GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 55 | 53 | | |
| Units: Percentage of participants | 9 | 15 | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Treatment Arm 1 Versus Treatment Arm 2 |
| Comparison groups | GSK3228836 300 mg (24 weeks) + PegIFN 180 mcg (24 weeks) v GSK3228836 300 mg (12 weeks) + PegIFN 180 mcg (24 weeks) |
| Number of subjects included in analysis | 108 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[71] |
| Parameter estimate | Difference in SVR Rate |
| Point estimate | -3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -29 |
| upper limit | 11 |

Notes:

[71] - The point estimate of SVR and its 95% highest posterior density Credible Interval (CI) are estimated from a Bayesian model that incorporates the analysis stratification factors and treatment arm.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 72

Adverse event reporting additional description:

All-cause mortality, Serious adverse events and non-serious adverse events were reported for the Safety Population who were randomized and received at least one dose of study treatment.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 26.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | GSK3228836 (12 weeks) + PegIFN (24 weeks) |
|-----------------------|---|

Reporting group description:

Participants on stable NA therapy received 300mg GSK3228836 for 12 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 microgram per week (mcg/week) up to 24 weeks.

| | |
|-----------------------|---|
| Reporting group title | GSK3228836 (24 weeks) + PegIFN (24 weeks) |
|-----------------------|---|

Reporting group description:

Participants on stable NA therapy received 300mg GSK3228836 for 24 weeks (plus a loading dose on Day 4 and 11), followed by PegIFN 180 microgram per week (mcg/week) up to 24 weeks.

| Serious adverse events | GSK3228836 (12 weeks) + PegIFN (24 weeks) | GSK3228836 (24 weeks) + PegIFN (24 weeks) | |
|---|---|---|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 6 / 55 (10.91%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Chest injury | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drug-induced liver injury | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Spinal stenosis | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | GSK3228836 (12 weeks) + PegIFN (24 weeks) | GSK3228836 (24 weeks) + PegIFN (24 weeks) | |
|---|--|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 50 / 53 (94.34%) | 52 / 55 (94.55%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Varicose vein | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 5 / 53 (9.43%) | 9 / 55 (16.36%) | |
| occurrences (all) | 8 | 19 | |
| Asthenia | | | |
| subjects affected / exposed | 10 / 53 (18.87%) | 5 / 55 (9.09%) | |
| occurrences (all) | 21 | 8 | |
| Chills | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 3 / 55 (5.45%) | |
| occurrences (all) | 2 | 5 | |
| Discomfort | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Facial pain | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Influenza like illness | | | |

| | | |
|-------------------------------|------------------|------------------|
| subjects affected / exposed | 8 / 53 (15.09%) | 12 / 55 (21.82%) |
| occurrences (all) | 12 | 14 |
| Pain | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 2 / 55 (3.64%) |
| occurrences (all) | 2 | 7 |
| Pyrexia | | |
| subjects affected / exposed | 14 / 53 (26.42%) | 17 / 55 (30.91%) |
| occurrences (all) | 19 | 25 |
| Vaccination site pain | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Malaise | | |
| subjects affected / exposed | 3 / 53 (5.66%) | 7 / 55 (12.73%) |
| occurrences (all) | 3 | 11 |
| Injection site bruising | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 2 / 55 (3.64%) |
| occurrences (all) | 7 | 13 |
| Injection site pain | | |
| subjects affected / exposed | 11 / 53 (20.75%) | 7 / 55 (12.73%) |
| occurrences (all) | 102 | 56 |
| Injection site erythema | | |
| subjects affected / exposed | 22 / 53 (41.51%) | 20 / 55 (36.36%) |
| occurrences (all) | 208 | 112 |
| Injection site pruritus | | |
| subjects affected / exposed | 11 / 53 (20.75%) | 10 / 55 (18.18%) |
| occurrences (all) | 118 | 36 |
| Injection site induration | | |
| subjects affected / exposed | 3 / 53 (5.66%) | 7 / 55 (12.73%) |
| occurrences (all) | 17 | 9 |
| Injection site discolouration | | |
| subjects affected / exposed | 3 / 53 (5.66%) | 5 / 55 (9.09%) |
| occurrences (all) | 12 | 17 |
| Injection site swelling | | |
| subjects affected / exposed | 5 / 53 (9.43%) | 2 / 55 (3.64%) |
| occurrences (all) | 32 | 8 |
| Injection site warmth | | |

| | | | |
|--|----------------|----------------|--|
| subjects affected / exposed | 3 / 53 (5.66%) | 1 / 55 (1.82%) | |
| occurrences (all) | 77 | 44 | |
| Injection site discomfort | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 55 (1.82%) | |
| occurrences (all) | 5 | 38 | |
| Injection site haematoma | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Injection site nodule | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Injection site anaesthesia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 2 | |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 2 / 55 (3.64%) | |
| occurrences (all) | 1 | 4 | |
| Reproductive system and breast disorders | | | |
| Heavy menstrual bleeding | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 2 | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Breast swelling | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Erectile dysfunction | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pelvic pain | | | |

| | | | |
|---|----------------|----------------|--|
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Pruritus genital | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Prostatitis | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 2 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 55 (1.82%) | |
| occurrences (all) | 3 | 1 | |
| Dry throat | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Laryngeal discomfort | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nasal obstruction | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 2 / 55 (3.64%) | |
| occurrences (all) | 2 | 2 | |
| Pleural effusion | | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Rhinorrhoea | | | |
| subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Throat irritation | | | |
| subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 1 / 55 (1.82%) 1 | |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Depressed mood | | | |
| subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 2 / 55 (3.64%) 2 | |
| Depression | | | |
| subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 2 | 2 / 55 (3.64%) 2 | |
| Hyposomnia | | | |
| subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Insomnia | | | |
| subjects affected / exposed occurrences (all) | 4 / 53 (7.55%) 6 | 1 / 55 (1.82%) 1 | |
| Irritability | | | |
| subjects affected / exposed occurrences (all) | 3 / 53 (5.66%) 4 | 1 / 55 (1.82%) 1 | |
| Libido decreased | | | |
| subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 2 | 1 / 55 (1.82%) 1 | |
| Mood altered | | | |
| subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |

| | | | |
|---|----------------------|------------------------|--|
| Nervousness subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Sleep disorder subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Investigations | | | |
| Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 6 | 2 / 55 (3.64%) 3 | |
| Alanine aminotransferase increased subjects affected / exposed occurrences (all) | 6 / 53 (11.32%) 9 | 23 / 55 (41.82%) 36 | |
| Antineutrophil cytoplasmic antibody increased subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 2 | 1 / 55 (1.82%) 1 | |
| Antineutrophil cytoplasmic antibody positive subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 4 | |
| Aspartate aminotransferase increased subjects affected / exposed occurrences (all) | 6 / 53 (11.32%) 6 | 16 / 55 (29.09%) 21 | |
| Bilirubin conjugated increased subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 1 / 55 (1.82%) 1 | |
| Blood creatinine increased subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 2 | 2 / 55 (3.64%) 2 | |
| Blood phosphorus decreased subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |

| | | |
|---|----------------|-----------------|
| Blood pressure increased | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Blood thyroid stimulating hormone decreased | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Blood thyroid stimulating hormone increased | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Body temperature increased | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 3 / 55 (5.45%) |
| occurrences (all) | 8 | 3 |
| C-reactive protein increased | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Complement factor C3 decreased | | |
| subjects affected / exposed | 3 / 53 (5.66%) | 7 / 55 (12.73%) |
| occurrences (all) | 3 | 9 |
| Complement fragment Bb increased | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Creatinine renal clearance decreased | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 6 / 55 (10.91%) |
| occurrences (all) | 24 | 35 |
| Creatinine renal clearance increased | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Glomerular filtration rate decreased | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 2 / 55 (3.64%) |
| occurrences (all) | 2 | 2 |
| Haemoglobin decreased | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Hepatic enzyme increased | | |

| | | | |
|--|-----------------|------------------|--|
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Hepatitis B DNA increased | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 55 (3.64%) | |
| occurrences (all) | 0 | 2 | |
| Monocyte chemotactic protein-1 increased | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 55 (3.64%) | |
| occurrences (all) | 0 | 2 | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 8 / 53 (15.09%) | 14 / 55 (25.45%) | |
| occurrences (all) | 12 | 22 | |
| Platelet count decreased | | | |
| subjects affected / exposed | 5 / 53 (9.43%) | 10 / 55 (18.18%) | |
| occurrences (all) | 5 | 13 | |
| Red blood cell count decreased | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Thyroxine increased | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Transaminases increased | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 55 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 8 / 55 (14.55%) | |
| occurrences (all) | 7 | 14 | |
| Complement factor C4 decreased | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 8 / 55 (14.55%) | |
| occurrences (all) | 2 | 11 | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-----------------------------|----------------|----------------|--|
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Head injury | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Joint injury | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Ligament sprain | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Lip injury | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Wound complication | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Cardiac disorders | | | |
| Bundle branch block left | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 2 | |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 2 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Sinus bradycardia | | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Nervous system disorders | | | |
| Presyncope | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dizziness | | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 3 / 55 (5.45%) | |
| occurrences (all) | 4 | 4 | |
| Headache | | | |
| subjects affected / exposed | 12 / 53 (22.64%) | 7 / 55 (12.73%) | |
| occurrences (all) | 25 | 29 | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 3 | |
| Migraine | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 55 (1.82%) | |
| occurrences (all) | 2 | 1 | |
| Muscle contractions involuntary | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 2 / 55 (3.64%) | |
| occurrences (all) | 3 | 2 | |
| Sensory disturbance | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Tension headache | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 8 | 0 | |
| Tremor | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 11 | |
| Somnolence | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Blood and lymphatic system disorders | | | |
| Agranulocytosis | | | |

| | | | |
|-----------------------------|------------------|------------------|--|
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 3 / 55 (5.45%) | |
| occurrences (all) | 3 | 3 | |
| Coagulopathy | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 11 / 53 (20.75%) | 14 / 55 (25.45%) | |
| occurrences (all) | 16 | 20 | |
| Neutropenia | | | |
| subjects affected / exposed | 12 / 53 (22.64%) | 10 / 55 (18.18%) | |
| occurrences (all) | 21 | 25 | |
| Neutrophilia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Leukopenia | | | |
| subjects affected / exposed | 7 / 53 (13.21%) | 10 / 55 (18.18%) | |
| occurrences (all) | 10 | 18 | |
| Ear and labyrinth disorders | | | |
| Ear pain | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 2 | |
| Ear pruritus | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tinnitus | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |

| | | | |
|-----------------------------|----------------|----------------|--|
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Dry eye | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Eye pain | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 55 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Iridocyclitis | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Meibomian gland dysfunction | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Visual impairment | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Vitreous floaters | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Xerophthalmia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| Abdominal tenderness | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 2 / 55 (3.64%) | |
| occurrences (all) | 1 | 2 | |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Abdominal pain | | | |

| | | |
|----------------------------------|-----------------|----------------|
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 12 |
| Abdominal pain upper | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 4 / 55 (7.27%) |
| occurrences (all) | 4 | 8 |
| Anal blister | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Colitis | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Constipation | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 0 / 55 (0.00%) |
| occurrences (all) | 5 | 0 |
| Diarrhoea | | |
| subjects affected / exposed | 6 / 53 (11.32%) | 3 / 55 (5.45%) |
| occurrences (all) | 6 | 3 |
| Dry mouth | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 1 |
| Dyspepsia | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 2 / 55 (3.64%) |
| occurrences (all) | 4 | 3 |
| Gastritis | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Gastrointestinal disorder | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Gastrooesophageal reflux disease | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Gingival bleeding | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gingival pain | | |

| | | | |
|--|----------------------|-----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Hypoaesthesia oral subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Malocclusion subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Nausea subjects affected / exposed occurrences (all) | 6 / 53 (11.32%) 6 | 8 / 55 (14.55%) 14 | |
| Oral mucosal blistering subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Proctalgia subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Toothache subjects affected / exposed occurrences (all) | 3 / 53 (5.66%) 4 | 2 / 55 (3.64%) 3 | |
| Vomiting subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 2 | 2 / 55 (3.64%) 3 | |
| Aphthous ulcer subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Hepatobiliary disorders Hepatic function abnormal subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 2 | 3 / 55 (5.45%) 5 | |
| Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 1 / 55 (1.82%) 1 | |
| Acne | | | |

| | | |
|-----------------------------|-----------------|----------------|
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Alopecia | | |
| subjects affected / exposed | 6 / 53 (11.32%) | 3 / 55 (5.45%) |
| occurrences (all) | 6 | 3 |
| Angioedema | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Dermatitis | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 2 | 0 |
| Dermatitis allergic | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Dermatitis contact | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 55 (0.00%) |
| occurrences (all) | 2 | 0 |
| Dry skin | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Ecchymosis | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Erythema | | |
| subjects affected / exposed | 3 / 53 (5.66%) | 2 / 55 (3.64%) |
| occurrences (all) | 3 | 3 |
| Nail ridging | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Petechiae | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 1 |
| Pruritus | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 5 / 55 (9.09%) |
| occurrences (all) | 5 | 5 |
| Psoriasis | | |

| | | | |
|---|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 2 | 0 / 55 (0.00%) 0 | |
| Purpura subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Rash subjects affected / exposed occurrences (all) | 2 / 53 (3.77%) 2 | 3 / 55 (5.45%) 5 | |
| Rash macular subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Rash papular subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Skin discolouration subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 7 | |
| Skin lesion subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Urticaria subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Erythema multiforme subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Renal and urinary disorders Chronic kidney disease subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Diabetic nephropathy subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Dysuria subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |

| | | | |
|---|-----------------------|---------------------|--|
| Haematuria subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Pollakiuria subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Renal impairment subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 1 / 55 (1.82%) 1 | |
| Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Hypothyroidism subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Musculoskeletal and connective tissue disorders Flank pain subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 2 / 55 (3.64%) 2 | |
| Arthralgia subjects affected / exposed occurrences (all) | 9 / 53 (16.98%) 13 | 4 / 55 (7.27%) 5 | |
| Arthritis subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Back pain subjects affected / exposed occurrences (all) | 4 / 53 (7.55%) 5 | 3 / 55 (5.45%) 9 | |
| Hip deformity subjects affected / exposed occurrences (all) | 1 / 53 (1.89%) 1 | 0 / 55 (0.00%) 0 | |
| Muscle spasms subjects affected / exposed occurrences (all) | 0 / 53 (0.00%) 0 | 1 / 55 (1.82%) 1 | |
| Musculoskeletal chest pain | | | |

| | | | |
|-----------------------------------|------------------|-----------------|--|
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 55 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Myalgia | | | |
| subjects affected / exposed | 12 / 53 (22.64%) | 6 / 55 (10.91%) | |
| occurrences (all) | 25 | 9 | |
| Neck pain | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 7 | 1 | |
| Osteoporosis | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 1 / 55 (1.82%) | |
| occurrences (all) | 3 | 2 | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 1 / 55 (1.82%) | |
| occurrences (all) | 1 | 1 | |
| Spinal pain | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Temporomandibular joint syndrome | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Limb discomfort | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Infections and infestations | | | |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 2 / 55 (3.64%) | |
| occurrences (all) | 5 | 2 | |

| | | |
|-----------------------------|----------------|------------------|
| Acute sinusitis | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| COVID-19 | | |
| subjects affected / exposed | 5 / 53 (9.43%) | 15 / 55 (27.27%) |
| occurrences (all) | 5 | 15 |
| Chlamydial infection | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Cystitis | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Folliculitis | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Gingivitis | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gonorrhoea | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Herpes dermatitis | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 2 | 0 |
| Hordeolum | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Influenza | | |
| subjects affected / exposed | 2 / 53 (3.77%) | 0 / 55 (0.00%) |
| occurrences (all) | 3 | 0 |
| Laryngitis | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |
| Localised infection | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 |

| | | | |
|------------------------------------|----------------|-----------------|--|
| Nasopharyngitis | | | |
| subjects affected / exposed | 5 / 53 (9.43%) | 2 / 55 (3.64%) | |
| occurrences (all) | 7 | 2 | |
| Oral herpes | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Otitis media | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pulmonary tuberculosis | | | |
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 3 / 55 (5.45%) | |
| occurrences (all) | 0 | 4 | |
| Viral infection | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |
| Metabolism and nutrition disorders | | | |
| Cell death | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 2 / 55 (3.64%) | |
| occurrences (all) | 0 | 2 | |
| Decreased appetite | | | |
| subjects affected / exposed | 4 / 53 (7.55%) | 7 / 55 (12.73%) | |
| occurrences (all) | 4 | 7 | |
| Gout | | | |

| | | | |
|-----------------------------|----------------|----------------|--|
| subjects affected / exposed | 1 / 53 (1.89%) | 0 / 55 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 53 (0.00%) | 1 / 55 (1.82%) | |
| occurrences (all) | 0 | 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|--|
| 16 October 2020 | Original Protocol |
| 24 September 2021 | Protocol Amendment 01: This amendment is considered to be non-substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/Ethics Committee (EC) of the European Parliament and the Council of the European Union because it neither significantly impacts the safety or physical/mental integrity of participants nor the scientific value of the study. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported